Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $5.64 Million - $6.31 Million
-97,508 Reduced 64.45%
53,791 $3.12 Million
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $3.19 Million - $3.54 Million
-50,063 Reduced 24.86%
151,299 $9.68 Million
Q1 2023

Apr 14, 2023

BUY
$65.71 - $74.53 $388,806 - $440,994
5,917 Added 3.03%
201,362 $14 Million
Q4 2022

Feb 15, 2023

SELL
$68.48 - $81.09 $6.11 Million - $7.24 Million
-89,270 Reduced 31.35%
195,445 $14.1 Million
Q3 2022

Oct 27, 2022

BUY
$0.13 - $76.84 $178 - $105,731
1,376 Added 0.49%
284,715 $20.2 Million
Q2 2022

Aug 01, 2022

SELL
$72.62 - $79.98 $2.69 Million - $2.96 Million
-37,057 Reduced 11.57%
283,339 $21.8 Million
Q1 2022

Apr 26, 2022

BUY
$61.48 - $73.72 $289,386 - $347,000
4,707 Added 1.49%
320,396 $23.4 Million
Q4 2021

Feb 15, 2022

BUY
$53.63 - $62.52 $1.28 Million - $1.49 Million
23,788 Added 8.15%
315,689 $19.7 Million
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $2.36 Million - $2.77 Million
39,927 Added 15.85%
291,901 $17.3 Million
Q2 2021

Jul 19, 2021

SELL
$61.91 - $67.42 $937,503 - $1.02 Million
-15,143 Reduced 5.67%
251,974 $16.8 Million
Q1 2021

May 03, 2021

BUY
$59.34 - $66.74 $236,469 - $265,958
3,985 Added 1.51%
267,117 $16.9 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $589,929 - $668,498
10,217 Added 4.04%
263,132 $16.3 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $142,483 - $157,890
-2,481 Reduced 0.97%
252,915 $15.2 Million
Q2 2020

Jul 29, 2020

BUY
$54.82 - $64.09 $517,555 - $605,073
9,441 Added 3.84%
255,396 $15 Million
Q1 2020

Apr 30, 2020

BUY
$46.4 - $67.43 $437,737 - $636,134
9,434 Added 3.99%
245,955 $13.7 Million
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $11.6 Million - $15.2 Million
236,521 New
236,521 $15.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Chartwell Investment Partners, LLC Portfolio

Follow Chartwell Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chartwell Investment Partners, LLC with notifications on news.